Drug Targets – Products

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.

Energy metabolism plays a central role in a wide variety of cellular and physiological processes. Therefore, a deep understanding of how disruption to energy metabolism impacts cells can help in therapeutic drug discovery and development.

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

Ubiquigent Limited today announced the appointment of Dr. Sheelagh Frame, Chief Scientific Officer, to the Company’s Board of Directors.

The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.

Cell coding company bit.bio has announced an expansion to its product portfolio to enable scientists to study neurodegenerative diseases in a human context.

Molecular Devices, LLC. and HeartBeat.bio AG, a biotech company developing cardiac organoids for drug discovery, have entered into a co-development agreement.

PhoreMost Ltd. today announced it has entered into a multi-project target discovery collaboration with Roche.

Bio-Rad Laboratories, Inc. today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin, secukinumab and the secukinumab–interleukin 17A drug-target complex.